Condition
Abatacept
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Early P 1 (1)
P 1 (1)
P 3 (1)
Trial Status
Unknown3
Clinical Trials (3)
Showing 3 of 3 trials
NCT04686929Phase 1UnknownPrimary
Abatacept s.c. for aGVHD Prevention in Haplo-HCT
NCT05451615Phase 3UnknownPrimary
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
NCT04946669Early Phase 1Unknown
An Exploratory Study on the Efficacy and Safety of Abatacept in the Treatment of Refractory Dermatomyositis
Showing all 3 trials